Stifel analyst Annabel Samimy reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Cara Therapeutics (CARA) PT Raised to $33 at JefferiesMay 29, 2019 11:20 AM Cara Therapeutics (CARA) to Resume Trading at 7:30 am ETMay 29, 2019 7:04 AM Cara Therapeutics (CARA) Phase 3 Trial of KORSUVA Injection in Hemodialysis Patients with Pruritus Met Primary EndpointMay 29, 2019 7:02 AM Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with PruritusMay 29, 2019 7:01 AM Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with PruritusMay 29, 2019 7:01 AM Cara Therapeutics (CARA) Halted, News PendingMay 29, 2019 6:55 AM Cara Therapeutics (CARA) option implied volatility elevated into ongoing Phase III trialsMay 29, 2019 6:07 AM Stocks with Implied Volatility MovementMay 29, 2019 4:40 AM Stocks with Implied Volatility MovementMay 28, 2019 3:59 AM